Snapshot of the Week: AbbVie

My Snapshot of the Week gives you a short summary of a stock that currently looks particularly interesting to me.

This week’s focus: US biopharmaceutical company AbbVie.


My Stock Screener

I use my own stock screener to identify companies that perfectly fit my investment strategy. It determines the attractiveness of a stock based on 4 assessment criteria and finally leads to my personal screening result, which I call Dividend Diary score (also DD score or fka JiR score).

More information about my stock screening process can be found here:

Companies with a Dividend Diary score of

AbbVie in my Stock Screener

AbbVie currently scores a Dividend Diary score of 1.0 minus points.

Conclusion: AbbVie is on my Watchlist

With a JiR score of 1.0 minus points, AbbVie is a candidate for my watchlist. But for now, I limit myself to sell put options with a strike price within my target price range.

What do you think about investing in biopharmaceutical companies like AbbVie? Please let me know and leave a short comment or contact me on Facebook or Twitter!

If you liked this week’s snapshot, you’re also welcome to have a look at my stock series. Here you can find all companies that already went through my stock screener.

Full transparency: All of my stocks, funds, bonds and options are subject to multiple risks. However, I’m neither a financial nor an investment professional. Hence, the presented information is not to be understood as any financial advice or recommendation. I’m not liable for any losses or suffering experienced by any party. More detailed information is available here (only in German).

2 Replies to “Snapshot of the Week: AbbVie”

    1. Hi Alex,

      From a quantitative point of view, I’m totally with you. That’s why AbbVie scores so well in our stock screener. There is no other dividend paying biotech company that comes even close to AbbVie’s JiR score.

      However, I’m a bit afraid of the company’s dependence on Humira and the expiration of AbbVie’s patent. Therefore, I still can’t make up my mind about whether to initiate a position.

      – David

Leave a Reply

Your email address will not be published. Required fields are marked *